DigestRedComo funciona
Red
/
Empresas
La
No verificado

Latus Bio, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaIndustriaSalud

8 Comunicados de prensa

Ver todos los comunicados de prensa
16/06/2026
Mercado laboral
Ciencia
Biotecnología
Medicina - Varios
Salud
Farmacéutica
Sanidad
Latus Bio Appoints Bethany Mancilla as Chief Business Officer
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
04/05/2026
Ciencia
Biotecnología
Medicina - Varios
Salud
Farmacéutica
Sanidad
Latus Bio Announces $97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger Populations
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
28/04/2026
Eventos
Ferias y Congresos
Industria
Ciencia
Biotecnología
Sanidad
Salud
Medicina - Varios
Latus Bio to Present New Data at ASGCT 2026 Supporting Investigational Gene Therapy Approaches for Huntington’s Disease and CLN2 Disease
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
02/12/2025
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Infancia
Ir de compras
Latus Bio Announces IND Clearance of LTS-101 for CLN2 Disease and Receipt of Fast Track, Orphan Drug, and Rare Pediatric Disease Designations
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
03/11/2025
Ciencia
Biotecnología
Salud
Técnica
Mercado laboral
Industria
Latus Bio Launches AI/ML Strategy to Transform AAV Gene Therapy, Adds Two Leading Experts in Peptide and Protein Modeling to Scientific Advisory Board
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
20/05/2025
Industria
Ciencia
Biotecnología
Sanidad
Salud
Farmacéutica
Latus Bio Announces Publication of Breakthrough Research on Novel AAV Capsid Variant for Huntington’s and Parkinson’s Disease Gene Therapy
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
14/05/2025
Industria
Salud
Biotecnología
Ciencia
Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
24/02/2025
Eventos
Ferias y Congresos
Industria
Salud
Biotecnología
Sanidad
Farmacéutica
Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0